Below please find a selective list of recent presentations:

Preview:

Institute for Quality and Efficiency in Health Care (IQWiG),
Autumn Symposium 2009
Cologne, Germany, November 27-28, 2009:

"Measures of Efficiency in Health Care"
[" Effizienzmaße im Gesundheitswesen"]

Akademie für Palliativmedizin und Hospizarbeit Dresden:
Tagung "Welches Leben ist mehr wert? Wie knappe Güter im Medizinsystem gerecht zu verteilen sind."
Dresden, Germany, June 19-20, 2009:

"A Note on the Meaning of 'Efficiency' in Health Care"
["Was bedeutet Effizienz im Gesundheitswesen?"]

Symposium of the Konrad Adenauer Foundation
Schwerin, Germany, March 20-21, 2009:
"Europäisierung der Gesundheitssysteme? Blick ins Ausland, Perspektiven für Deutschland"

"Innovation in German Health Care"
["Wie innovationsfreudig ist das deutsche Gesundheitssystem?"]

The Galen Institute, Washington, DC:
Washington, DC, March 09, 2009:

Lessons from abroad for health care reform in the U.S.
"A global perspective on comparative effectiveness programs"

Recent:

London School of Economics (LSE)
"Market Access Master Class"
Brussels, Belgium, February 18-20, 2009:

"Current and Future Role of Health Technology Assessment (HTA) in Health Care Decision Making"

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 11th Annual European Congress,
Athens, Greece, November 08-11, 2008:

1. Expensive drugs for rare disorders and the logic of cost-effectiveness

2. How much might we be prepared to pay for psychosocial interventions for patients with attention-deficit/hyperactivity disorder (ADHD)?

3. Cost-effectiveness of long-acting methylphenidate for treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in Finland: an evaluation based upon a randomized clinical trial (RCT)

4. Health service expenditures for patients with a diagnosis of attention-deficit/hyperactivity disorder (ADHD) in Germany - an age and gender specific analysis

5. Health service expenditures for children and adolescents with and without attention-deficit/hyperactivity disorder (ADHD) in Germany - impact of coexisting conditions

6. Prevalence of tic disorders and coexistence with attention-deficit/hyperactivity disorder (ADHD) in a German community sample

7. Administrative prevalence of psoriasis in Germany

OÖ Ordensspitäler: 6th International Congress
"Wertewandel in der Medizin - ein neuer medizinischer Wertekanon?"
Design Center Linz, Austria, November 06, 2008:

"Warum und wie unterscheiden sich zentrale Wertvorstellungen von Ärzten und Ökonomen?"

The Galen Institute, Washington, DC:
Washington, DC, October 30, 2008:

Comparative Effectiveness:
A Perspective from Europe

16th Cochrane Colloquium: "Evidence in the era of globalisation" - Freiburg, Germany, October 03-07, 2008:

Symposium "Can we bridge the gap between evidence-based medicine and economic evaluation?"

Marketing-Club Südhessen
Darmstadt, Germany, October 6, 2008:

"Ende des Pharma-Marketing - Steht das Marketing der forschenden Arzneimittelunternehmen vor dem Aus?"

The Institute for Innovation &Valuation in Health Care
organiized a high-level

Health Economics Summer School

in Heidelberg from September 29 to October 02, 2008. Details of the scientific program are available online at the Institute's website.

3. Deutscher Atherosklerosekongress
Mannheim, Germany, September 18-20, 2008:

"Coronary Artery Disease:
Health Care Utilization and Economics"
["Versorgungsaspekte bei Koronarer Herzkrankheit (KHK)"]

London School of Economics (LSE)
Workshop "Valuation in Health Care"
Lisboa, Portugal, June 28, 2008:

Concepts of Value in Health Care:
A Note on Value, Valuation, and Values Talk.

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 13th Annual International Meeting,
Toronto, ON, May 03-07, 2008:

Contributed Issues Panel, "QALYs Gone Wild?", with Adrian Griffin (High Wycombe, Buckinghamshire), Peter I. Juhn (New Brunswick, NJ), and Peter J. Neumann (Boston, MA)

University of Heidelberg, Germany
Inaugural Address, Mannheim, December 14, 2007, 2 p.m.:

M. Schlander:
"Economic Evaluation of Health Care Programs: The Case of ADHD" (delivered in German: "Leistungsfähigkeit und Limitationen gesundheitsökonomischer Evaluationen am Beispiel der ADHS"

At the MEDICA Congress in Duesseldorf, November 16, 2007, a roundtable discussion was devoted to issues surrounding the future of "cost-benefit evaluation" in German health care and the role of the Institute for Quality and Efficiency in Health Care (IQWiG).

The Institute for Innovation &Valuation in Health Care
offered a high-level

Health Economics Summer School

in Heidelberg from September 24-28, 2007,

comprising of an interactive one-week program focused on the foundations of (part A, September 24-25) and international experience with (part B, September 25-28) the economic evaluation of health care interventions.

13th International Congress of the European Society for Child and Adolescent Psychiatry (ESCAP), Florence, August 25-29, 2007:

M. Schlander:
Cost-Effectiveness of ADHD Treatment Strategies:
What We Do Know... and What We Do Not Know ...

6th World Congress of the International Health Economics Association (iHEA), Copenhagen, July 8-11, 2007:

M. Schlander:
Lost in Translation? Over-Reliance on QALYs May Lead to Neglect of Relevant Evidence.
6th iHEA World Congress, Copenhagen, July 9, 2007

XLII Zjazd Psychiatrów Polskich, 14-16 czerwca 2007, Szczecin
[Triennual Congress of the Polish Psychiatric Association, Stettin, June 14-16, 2007]:

M. Schlander:
Leki dlugo-dzialajace na zespól nadruchliwosci z deficytami uwagi (ADHD): Czy mozliwe jest uzasadnienie ich uzycia z perspektywy ekonomicznej? [Can we Justify the Use of Long-Acting Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) from an Economic Perspective?] - invited presentation.
Psychiatria Polska, Tom XLI Nr 3 - 2007, Suplement, 148.

Recent presentations include nine scientific posters on original research at the upcoming meeting of the International Center of Mental Health Policy and Economics in Venice, March 9-11, 2007: "Investing in Mental Health Policy and Econcomics Research".

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 9th Annual European Congress,
Copenhagen, October 29-31, 2006:

M. Schlander, O. Schwarz, L. Hakkaart-van Roijen, P.S. Jensen, U. Persson, P. Santosh, G.-E. Trott, and the MTA Cooperative Group:

1. Cost-Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States, Germany, The Netherlands, Sweden, and United Kingdom
Value in Health 9 [6] (2006) A312

2. Functional Impairment of Patients
with Attention-Deficit/Hyperactivity Disorder (ADHD):
An Alternative Cost-Effectiveness Analysis of Clinically Proven Treatment Strategies based upon the NIMH MTA Study
Value in Health 9 [6] (2006) A312

3. Cost-Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/Hyperactivity Disorder (ADHD):
Impact of Coexisting Conditions
Value in Health 9 [6] (2006) A309

M. Schlander, O, Schwarz, M. Viapiano, N. Bonauer:
Methylphenidate Prescriptions for Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD):
New Data from Nordbaden/Germany
Value in Health 9 [6] (2006) A191-192

M. Schlander, O, Schwarz, M. Viapiano, N. Bonauer:
Off-Label Utilization of methylphenidate (MPH) in Adults with Attention-Deficit/Hyperactivity Disorder (ADHS) in Germany: Insights from the Nordbaden Project
Value in Health 9 [6] (2006) A311

Monash University,
Melbourne, Victoria (Australia)
Centre for Health Economics Seminar Series,
September 14, 2006:

M. Schlander:
"Has NICE Got It Right?"
Health Technology Assessments (HTAs)
by the National Institute for Health and Clinical Excellence

17th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP),
Melbourne, Vic, September 10-14, 2006:

M. Schlander:
Cost-Effectiveness of Treatment Options
for Attention-Deficit/Hyperactivity Disorder (ADHD)
in Children and Adolescents:
What Have We Learnt?
IACAPAP 2006 Book of Abstracts (#2040)

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer:
Who Cares for Patients with Attention-Deficit/Hyperactivity Disorder (ADHD)?
Insights from Nordbaden, Germany
IACAPAP 2006 Book of Abstracts (#2041)

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer:
Age and Gender Specific Comorbidity Profiles of Patients with a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD):
Administrative Data from Nordbaden, Germany
IACAPAP 2006 Book of Abstracts (#7024)

International Conference
"ADHD - New Insights and Implications",
Evangelische Akademie Bad Boll, February 17-19, 2006:

M. Schlander:
New Evidence on Attention-Deficit/Hyperactivity Disorder (ADHD):
1. Diagnosis of ADHD: By whom and how often?
2. Cost-Effectiveness of ADHD Treatment Strategies

Symposium
"Targeted Therapy - New Perspectives in Oncology?",
National Center for Tumor Diseases (NCT),
Heidelberg / Germany, February 04, 2006:

M. Schlander:
Can We Afford "Targeted Therapies"?

Pharmaceutical Round Table, Landesapothekerkammer Baden-Wuerttemberg, Stuttgart / Germany, December 06, 2005:

M. Schlander:
Health Economics: Is Germany a Developing Country?

7th Congress of the German Working Party on Endoprothetics, Heidelberg / Germany, December 03, 2005:

M. Schlander:
Poltics and Economics: An Issue of Leadership?
Plus 100% in 30 Years - Can We Still Manage the System?

Annual Meeting 2005 of the German Association of Child and Adolescent Psychiatrists and Psychologists (Jahrestagung 2005 des Berufsverbandes der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie in Deutschland, BKJPP), Wuerzburg, November 16-19, 2005:

M. Schlander: Zur Zukunft der fachärztlichen Versorgung in Deutschland (Presentation & Discussion).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 8th Annual European Congress,
Florence, Italy, November 06-08, 2005:

M. Schlander, O. Schwarz:
The Nordbaden Project for Health Care Utilization Research in Germany: Database Characteristics and First Application.
Value in Health 8 [6] (2005) A199

M. Schlander, O. Schwarz, G.-E. Trott, E. Taylor, P. Santosh,
P.S. Jensen, E.M. Foster, J.A. Garcia, S. Glied, M. Crowe,
MTA Cooperative Group:
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD):
Are U.S. cost-effectiveness findings based upon the MTA Study relevant to mental health care policy makers in Germany?
Value in Health 8 [6] (2005) A197

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer:
Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents: Mental Health and Physical Co-Morbidity in Nordbaden / Germany.
Value in Health 8 [6] (2005) A196-197

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer:
Attention-Deficit/Hyperactivity Disorder (ADHD) in Grown-Ups: Administrative Data on Co-Existing Conditions.
Value in Health 8 [6] (2005) A196
Winner of ISPOR Contributed Research Award
for Best Poster Presentation (out of ~750 Posters)

Joint Annual Meeting 2005 of the American Academy of
Child & Adolescent Psychiatry (AACAP, 52nd Annual Meeting) and the Canadian Academy of Child and Adolescent Psychiatry (CACAP, 25th Annual Meeting), Toronto, ON,
October 18-23, 2005:

L. Eugene Arnold, B. Molina, J. Swanson, J. Epstein,
M. Schlander, P. Jensen:
New ADHD Insights from MTA Data Through 36 Months.
Scientific Proceedings, 25, p.54

M. Schlander and the MTA Cooperative Group:
Cost-Effectiveness of ADHD Treatments by Diagnostic Subgroups and Comorbidity.
Scientific Proceedings, 25D, p. 55

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer:
Administrative Prevalence and Comorbidity of ADHD in Children and Adolescents - Evidence from Nordbaden / Germany.
Scientific Proceedings, C69, p. 150

Colloquium on Pharmaceutical Industry Perspectives,
Princeton, NJ, October 18, 2005:

M. Schlander: The German Pharmaceutical Market - Perspectives after the Federal Elections of 2005.

5th World Congress of the International Health Economics Association (iHEA),
Barcelona, July 2005:

M. Schlander: Health economic evaluation of medical interventions: answering questions people are unwilling to ask?
5th iHEA World Congress, Barcelona, July 9-13, 2005:
Book of Abstracts, pp. 354-355.

10th Annual "Handelsblatt"
Meeting of the Pharmaceutical Industry,
Berlin, March 16-17, 2005:

M. Schlander (Moderator): "NICE - A Model for Germany?"
Plenum Roundtable Discussion with Martin Buxton (Professor of Health Economics, Brunel University), Andrew Dillon (CEO, NICE), Rainer Hess (Head of the German Federal Joint Committee, Gemeinsamer Bundesausschuss),
and Stefan Oschmann (VP Europe, MSD).

Annual Meeting 2004 of the German Association of Child and Adolescent Psychiatrists and Psychologists (Jahrestagung 2004 des Berufsverbandes der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie in Deutschland, BKJPP), Gelsenkirchen, November 11, 2004:

M. Schlander: Was kann die Gesundheitsökonomie zu einer effektiven und effizienten Versorgung in der Kinder- und Jugendpsychiatrie beitragen? (Invited Speaker).

M. Schlander, G.-E. Trott, K. Migliaccio-Walle, J. Caro: Kosteneffektivität verbesserter Compliance mit medikamentöser Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Kindern und Jugendlichen aus der Perspektive der Gesetzlichen Krankenversicherung. (Poster)
Book of Abstracts, BKJPP-Jahrestagung 2004, p. 23.

M. Schlander, P.S. Jensen, E.M. Foster, J.A. Garcia, S. Glied, M. Crowe, MTA Cooperative Group: Kosteneffektivität alternativer Behandlungsstrategien der Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS): Schätzungen auf Basis der amerikanischen MTA-Studie. (Poster)
Book of Abstracts, BKJPP-Jahrestagung 2004, p. 21.

Fall Symposium of the German Society of Internal Medicine (Herbstsymposium des Vorstandes der Deutschen Gesellschaft für Innere Medizin, DGIM),
Wiesbaden, October 27, 2004:

M. Schlander: Qualitätsverlust durch ökonomische Steuerung in der Arzneimitteltherapie? Auswirkungen der Sozialgesetzgebung und Situation des deutschen Arzneimittelmarktes im internationalen Vergleich.
(Invited Speaker).

Annual Meeting of the Academy of Ethics in Medicine
(Jahrestagung der Akademie für Ethik in der Medizin):
„Gerechtigkeit im Gesundheitswesen. Ethische Probleme in Theorie und Praxis“.
Münster, September 30 - Oktober 2, 2004:

M. Schlander: Das Gesundheitswesen zwischen Finanzierbarkeit, Finanzierung und Finanzierungsbereitschaft: Zum Beitrag der Gesundheitsökonomie. (Oral Presentation)

100th Annual Meeting of the German Society for Pediatrics
(100. Jahrestagung der Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ) zusammen mit der Österreichischen Gesellschaft für Kinder- und Jugendheilkunde und der Deutschen Gesellschaft für Sozialpädiatrie und Jugendmedizin),
Berlin, September 9-12, 2004:

M. Schlander: Aufmerksamkeits-Defizit-Hyperaktivitäts-Störung (ADHS): Ökonomische Relevanz neuer therapeutischer Optionen aus der Perspektive niedergelassener Pädiater und der Gesetzlichen Krankenversicherung (GKV) in Deutschland. (Poster).
Monatsschrift für Kinderheilkunde, Vol. 152 (2004), Suppl. 1.

16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP),
Berlin, August 22-26, 2004:

M. Schlander: Budgetary Impact of Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in Germany: Increasing Relevance of Health Economic Evidence. (Oral Presentation)
Book of Abstracts, Steinkopff-Verlag, Darmstadt: 2004: S-111-516, p. 187

M. Schlander, K. Migliaccio-Walle, J.J. Caro: Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): Modeling the Cost-Effectiveness of a Modified-Release Preparation of Methylphenidate from the Perspective of the National Health Service (NHS) in the United Kingdom. (Oral Presentation)
Book of Abstracts, Steinkopff-Verlag, Darmstadt: 2004: S-112-522, p. 189

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 9th Annual International Meeting,
Arlington, VA, May 16-19, 2004:

M. Schlander, O. Schwarz, C. Thielscher: Estimating the Ability to Pay for Health Care Expenditures Rising Faster than GDP: An International Perspective Comparing the USA and Germany (Poster)
Value in Health 7 [3] (2004) 370

Sächsische Landesärztekammer
Symposium „Von der Schwierigkeit einer Bewertung des gesundheitsökonomischen Nutzens von Arzneimitteln“ (Chairman: Prof. Dr. Jan Schulze),
Dresden, December 10, 2003:

M. Schlander: Probleme der Kosten/Nutzen-Bewertung von Arzneimitteln. (Invited Speaker)

"Fourth Mannheim Symposium on Medical Ethics"
"Viertes Mannheimer Ethik-Symposium":
„Gesundheitswesen im Spannungsfeld zwischen Wirtschaftlichkeit und Menschlichkeit“,
University of Mannheim, September 27, 2003:

M. Schlander: Kosteneffektivität und Ressourcenallokation: Gibt es einen normativen Anspruch der Gesundheitsökonomie? (Invited Speaker)

Annual Meeting of the Association for Applied Human Pharmacology (Arbeitsgemeinschaft für angewandte Humanpharmakologie, AGAH),
Bonn, February 24, 2003:

M. Schlander: Socioeconomic aspects of new drugs: what does society want? (Invited Speaker; abstract published under www.biomedcentral.com)

Special Convention on ADHD:
“Ein Problem ist nicht genug: ADS und Hochbegabung ”,
Evangelische Akademie Bad Boll, February 23, 2003.

M. Schlander: Gesundheitsökonomische Aspekte von ADHS. (Invited Speaker)